Trial Profile
Retrospective analysis of efficacy of Gefitinib in Non Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 May 2017
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 May 2017 New trial record